NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 2016
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
5/8 — Partial
RAYALDEE (calcifediol) by Merck & Co. is (25-hydroxyvitamin d 3 ) is a prohormone of the active form of vitamin d 3 , calcitriol (1,25‑dihydroxyvitamin d 3 ). First approved in 2016.
Drug data last refreshed 6h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RAYALDEE (calcifediol) is an oral extended-release capsule containing 25-hydroxyvitamin D3, a prohormone that is converted to the active form of vitamin D3 (calcitriol) primarily in the kidney. It works by binding to vitamin D receptors to increase intestinal calcium and phosphorus absorption while reducing parathyroid hormone synthesis, indicated for secondary hyperparathyroidism in patients with stage 3-4 chronic kidney disease.
$0.041BPart D
Peak7.5 years to LOEProduct is at peak lifecycle stage with $41M in annual Part D spending and nearly 30K claims, indicating mature commercial operations with potential for modest team expansion rather than hypergrowth.
Mechanism of Action
(25-hydroxyvitamin D 3 ) is a prohormone of the active form of vitamin D 3 , calcitriol (1,25‑dihydroxyvitamin D 3 ). Calcifediol is converted to calcitriol by cytochrome P450 27B1 (CYP27B1), also called 1-alpha hydroxylase, primarily in the kidney. Calcitriol binds to the vitamin D receptor in…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency
Started Dec 2020
674 enrolled
Vitamin D DeficiencyVitamin D Insufficiency
Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Started Nov 2020
171 enrolled
COVID-19CoronavirusSARS-CoV2 Infection
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
Started May 2020
517 enrolled
SARS-CoV 2COVID19SARS (Severe Acute Respiratory Syndrome)+2 more
Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Started Jul 2018
44 enrolled
Secondary Hyperparathyroidism Due to Renal CausesChronic Kidney DiseasesVitamin D Deficiency+1 more
Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency
Started Jun 2018
69 enrolled
Secondary Hyperparathyroidism Due to Renal CausesVitamin D InsufficiencyCKD Stage 3+1 more
Worked on RAYALDEE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.